Nephrin and podocin mRNA detection in urine sediment of dogs with chronic kidney disease: preliminary observations

• Published in: Journal of veterinary research Vol. 66; no. 2; pp. 281 - 288
• Main Authors: Souza, Camilla de, Coelho, Mariana, Antonelo, Daniel Silva, Passarelli, Danielle, Rochetti, Arina Lázaro, Fukumasu, Heidge, Leite-Dellova, Deise Carla Almeida
• Format: Journal Article
• Language: English
• Published: Pulawy Sciendo 01.06.2022; De Gruyter Poland
• Subjects: dog; Glycogen; Kidney diseases; mRNA; nphs1; nphs2; podocyturia; quantitative real-time PCR; Sediments; Urine
• ISSN: 2450-8608; 2450-7393; 2450-8608
• DOI: 10.2478/jvetres-2022-0019

Abstract Introduction Dogs with chronic kidney disease (CKD) may have alterations in the glomerular filtration barrier, including podocyte loss. Detection of podocyte mRNA in urine could be useful for assessing podocyturia in dogs with kidney disease. The objective of this study was to evaluate the presence of nephrin mRNA ( NPHS1 ) and podocin mRNA ( NPHS2 ) in urine sediments of dogs with naturally occurring CKD and healthy dogs. Material and Methods Twenty-four dogs, 14 with CKD and 10 as healthy controls, underwent clinical evaluation. The dogs with CKD were divided into two groups, according to the International Renal Interest Society criteria: stage 1 or 2 CKD (n = 5) and stage 3 or 4 CKD (n = 9). Urine was collected by catheterisation or free catch and RNA isolation from the urine sediments was optimised using glycogen as a co-precipitant. Detection of NPHS1 and NPHS2 in the sediment samples was performed using quantitative real-time PCR. Results Both types of mRNA were detected in samples from all groups, but the percentages of detection were higher in the group of dogs with stage 1 or 2 CKD and lower in the group of dogs with stage 3 or 4 disease. Conclusion Physiological podocyturia was observed in healthy dogs, and the results suggest differential podocyturia in dogs with CKD, according to the stage of the disease, i.e . an increase in podocyturia in dogs at stage 1 or 2 and a reduction in podocyturia in dogs at stage 3 or 4.